Mode
Text Size
Log in / Sign up

Hyperoxygenation target (PaO2: 100-150 mmHg) reduces 28-day mortality in patients with sepsisHigher oxygen targets may lower death rates for sepsis patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider hyperoxygenation (PaO2: 100-150 mmHg) to reduce 28-day mortality in patients with sepsis.

This randomized controlled trial enrolled 270 patients with sepsis to evaluate different oxygenation targets. The study compared a hyperoxygenation target (PaO2: 100-150 mmHg) against both conservative and conventional oxygenation targets.

In the primary outcome of 28-day mortality, the hyperoxygenation group showed a rate of 18.7% (17/91). In contrast, the conventional group had a mortality rate of 34.4% (32/93), and the conservative group had a rate of 40.7% (35/86). These results were statistically significant (P = 0.005 between groups; P = 0.001 for conservative vs hyperoxygenation).

Secondary outcomes included 90-day mortality, mechanical ventilation use, and vasopressor use. For 90-day mortality, rates were 36.3% for hyperoxygenation, 41.9% for conventional, and 50.0% for conservative; however, these differences were not significant. No specific data on adverse events or tolerability were reported.

A primary limitation is the single-center design of the study. While the trial suggests a causal link between hyperoxygenation and reduced 28-day mortality, the lack of significant difference in 90-day outcomes should be noted when determining long-term clinical impact.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in management strategies for sepsis. While previous coverage identified biomarkers like HMGB1 that correlate with increased mortality risk and noted the role of NETs in vascular dysfunction, this study provides specific evidence on oxygenation targets. It complements existing knowledge by offering a targeted intervention to reduce 28-day mortality in patients diagnosed with sepsis.

Sepsis is a life-threatening medical emergency where the body's response to infection causes organ failure. When doctors treat these patients, they must decide how much oxygen to provide. This study looked at whether aiming for higher oxygen levels—called hyperoxygenation—helped patients survive longer than standard or conservative methods.

Researchers followed 270 patients with sepsis. They found that those who received the higher oxygen target had a much lower death rate within 28 days compared to those on conservative plans. Specifically, only 18.7% of the hyperoxygenation group died within 28 days, while over 40% of the conservative group did.

While the results for the first month were promising, the study did not show a significant difference in survival rates at the 90-day mark. Because this was a single-center study, more research is needed to see how these findings apply across different hospitals and patient types.

What this means for you:
Higher oxygen targets can significantly reduce death rates for sepsis patients within the first 28 days of treatment.

Common questions

What is hyperoxygenation and how does it work?

Hyperoxygenation means giving a patient a specific, higher target of oxygen in their blood (PaO2: 100-150 mmHg). In this study, patients receiving this higher target had a significantly lower death rate within 28 days compared to those on conservative plans. You should talk to a doctor about how these oxygen levels are managed during critical care.

Does more oxygen help sepsis patients survive longer?

The study found that higher oxygen targets reduced the number of deaths within 28 days for patients with sepsis. However, it is important to note that there was no significant difference in survival rates when looking at the 90-day mark. This suggests the benefit was most notable in the early stages of treatment.

How many people were involved in this study?

The trial included a total of 270 patients who were diagnosed with sepsis. Researchers compared three different oxygen targets to see which method best helped patients survive the initial period after their condition began.

Study Details

Study typeRct
Sample sizen = 86
EvidenceLevel 2
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Sepsis is a clinical syndrome marked by a dysregulated host response to infection, impairing oxygen delivery and utilization and causing organ dysfunction. Hypoxemia, which can cause significant tissue and organ damage, commonly occurs in sepsis. Thus, oxygen therapy is essential in patients with sepsis. However, the optimal oxygenation target for these patients remains controversial. OBJECTIVE: To evaluate the effects of different oxygenation targets on short- and medium-term outcomes in patients with sepsis. METHODS: A prospective, single-center, randomized controlled trial was conducted. The primary outcome was 28-day mortality. Secondary outcomes included 90-day mortality and intergroup comparisons of mechanical ventilation and vasopressor use during hospitalization. RESULTS: In total, 270 patients were randomly assigned to the conservative oxygenation, conventional oxygenation, and hyperoxygenation target groups (n = 86, 93, and 91), of whom 35 (40.7%), 32 (34.4%), and 17 (18.7%) died by day 28, respectively. The 28-day mortality significantly differed between these groups ( P = 0.005). Pairwise comparison revealed a significant difference between the conservative oxygenation and hyperoxygenation target groups (χ 2 = 10.132, P = 0.001). Kaplan-Meier analysis showed significant differences in survival distributions among the groups (χ 2 = 10.340, P = 0.006). The 90-day mortality rates were 50.0%, 41.9%, and 36.3% in the conservative oxygenation, conventional oxygenation, and hyperoxygenation target groups, respectively, exhibiting no significant difference. CONCLUSION: Compared with conservative oxygen therapy, hyperoxygenation (PaO 2 : 100-150 mmHg) reduced 28-day mortality in patients with sepsis. However, no significant differences were observed among oxygenation targets regarding 90-day outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.